7-30633729-C-T
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_002047.4(GARS1):c.2095-6C>T variant causes a splice region, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.601 in 1,612,332 control chromosomes in the GnomAD database, including 303,617 homozygotes. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Benign (★★).
Frequency
Consequence
NM_002047.4 splice_region, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GARS1 | NM_002047.4 | c.2095-6C>T | splice_region_variant, intron_variant | ENST00000389266.8 | NP_002038.2 | |||
GARS1 | NM_001316772.1 | c.1933-6C>T | splice_region_variant, intron_variant | NP_001303701.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GARS1 | ENST00000389266.8 | c.2095-6C>T | splice_region_variant, intron_variant | 1 | NM_002047.4 | ENSP00000373918.3 | ||||
GARS1 | ENST00000675651.1 | c.2113-6C>T | splice_region_variant, intron_variant | ENSP00000502513.1 | ||||||
GARS1 | ENST00000675810.1 | c.1993-6C>T | splice_region_variant, intron_variant | ENSP00000502743.1 | ||||||
GARS1 | ENST00000675693.1 | c.1927-6C>T | splice_region_variant, intron_variant | ENSP00000502174.1 | ||||||
GARS1 | ENST00000675051.1 | c.1894-6C>T | splice_region_variant, intron_variant | ENSP00000502296.1 | ||||||
GARS1 | ENST00000674815.1 | c.1726-6C>T | splice_region_variant, intron_variant | ENSP00000502799.1 | ||||||
GARS1 | ENST00000674851.1 | c.1726-6C>T | splice_region_variant, intron_variant | ENSP00000502451.1 | ||||||
GARS1 | ENST00000444666.6 | n.*516-6C>T | splice_region_variant, intron_variant | 3 | ENSP00000415447.2 | |||||
GARS1 | ENST00000674616.1 | n.*1809-6C>T | splice_region_variant, intron_variant | ENSP00000502408.1 | ||||||
GARS1 | ENST00000674643.1 | n.*1900-6C>T | splice_region_variant, intron_variant | ENSP00000501636.1 | ||||||
GARS1 | ENST00000674737.1 | n.*1433-6C>T | splice_region_variant, intron_variant | ENSP00000502464.1 | ||||||
GARS1 | ENST00000674807.1 | n.*368-6C>T | splice_region_variant, intron_variant | ENSP00000502814.1 | ||||||
GARS1 | ENST00000675529.1 | n.*1965-6C>T | splice_region_variant, intron_variant | ENSP00000501655.1 | ||||||
GARS1 | ENST00000675859.1 | n.*274-6C>T | splice_region_variant, intron_variant | ENSP00000502033.1 | ||||||
GARS1 | ENST00000676088.1 | n.*2037-6C>T | splice_region_variant, intron_variant | ENSP00000501884.1 | ||||||
GARS1 | ENST00000676140.1 | n.*1040-6C>T | splice_region_variant, intron_variant | ENSP00000502571.1 | ||||||
GARS1 | ENST00000676164.1 | n.*1546-6C>T | splice_region_variant, intron_variant | ENSP00000501986.1 | ||||||
GARS1 | ENST00000676210.1 | n.*1384-6C>T | splice_region_variant, intron_variant | ENSP00000502373.1 | ||||||
GARS1 | ENST00000676259.1 | n.*1527-6C>T | splice_region_variant, intron_variant | ENSP00000501980.1 | ||||||
GARS1 | ENST00000676403.1 | n.*180-6C>T | splice_region_variant, intron_variant | ENSP00000502681.1 |
Frequencies
GnomAD3 genomes AF: 0.487 AC: 73957AN: 151770Hom.: 21507 Cov.: 30
GnomAD3 exomes AF: 0.560 AC: 139586AN: 249068Hom.: 41588 AF XY: 0.563 AC XY: 76049AN XY: 135166
GnomAD4 exome AF: 0.613 AC: 894881AN: 1460442Hom.: 282113 Cov.: 42 AF XY: 0.608 AC XY: 441967AN XY: 726596
GnomAD4 genome AF: 0.487 AC: 73958AN: 151890Hom.: 21504 Cov.: 30 AF XY: 0.484 AC XY: 35937AN XY: 74202
ClinVar
Submissions by phenotype
not specified Benign:5
Benign, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | - | - - |
Benign, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | May 03, 2021 | - - |
Benign, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
not provided Benign:2
Benign, no assertion criteria provided | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Feb 15, 2016 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 03, 2015 | - - |
Charcot-Marie-Tooth disease type 2D Benign:2
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Aug 10, 2021 | - - |
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Neuronopathy, distal hereditary motor, type 5A Benign:2
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Aug 10, 2021 | - - |
Charcot-Marie-Tooth disease Benign:1
Benign, criteria provided, single submitter | clinical testing | Molecular Genetics Laboratory, London Health Sciences Centre | - | - - |
Distal spinal muscular atrophy Benign:1
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Spinal muscular atrophy, infantile, James type Benign:1
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Aug 10, 2021 | - - |
Charcot-Marie-Tooth disease type 2 Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at